B-cell development: pro-B, pre-B and the pre-BCR checkpoint
- Process
B cells are built in the bone marrow step by step: first the heavy chain, then a test, then the light chain; a broken step leaves the body without antibodies.
What it is
B lymphocytes develop in the bone marrow from haematopoietic stem cells through ordered stages defined by which antibody gene is being rearranged. The pre-B-cell receptor, made of a new heavy chain with a temporary surrogate light chain, is the key checkpoint: its signal through BTK tells the cell to multiply and move on to the light chain. Blocks at this checkpoint cause agammaglobulinaemia, and each stage has a malignant counterpart.
Step by step
- Haematopoietic stem cell → common lymphoid progenitor; the bone-marrow stroma supplies signals that commit it to the B lineage.
- Pro-B cell: RAG1/RAG2 and TdT rearrange the heavy-chain genes (D to J, then V to DJ).
- Pre-B cell: the new μ heavy chain pairs with the surrogate light chain (VpreB and λ5) and Igα/Igβ to form the pre-BCR.
- Pre-BCR signalling through BTK drives proliferation and stops rearrangement of the other heavy-chain allele (allelic exclusion).
- Light-chain genes rearrange, κ first and λ if κ fails, giving a complete IgM receptor: immature B cell.
- Self-reactive immature B cells edit their light chain, die or become anergic (central tolerance).
- Transitional B cells leave for the spleen and mature into naive B cells with IgM and IgD (alternative RNA splicing).
Stages, markers and related diseases
| Stage | What happens | Typical markers | Disease link |
|---|---|---|---|
| Pro-B | Heavy-chain rearrangement | CD34, CD19, CD10, TdT | B-lymphoblastic leukaemia arises from these precursors |
| Pre-B | Pre-BCR checkpoint, proliferation | CD19, CD10, cytoplasmic μ, CD20 begins | X-linked agammaglobulinaemia (BTK), μ-chain and λ5 defects |
| Immature B | Surface IgM, tolerance tests | CD19, CD20, surface IgM | Receptor editing failure contributes to autoimmunity |
| Mature naive B | IgM and IgD, leaves marrow | CD19, CD20, CD21, IgM⁺ IgD⁺ | Chronic lymphocytic leukaemia and mantle cell lymphoma are mature B-cell neoplasms |
| Plasma cell (after activation) | Secretes antibody | CD38, CD138; CD20 lost | Multiple myeloma |
Markers
- CD19 (pan-B)
- CD20 (pre-B to mature)
- CD10 (precursors, germinal centre)
- TdT (precursors)
- CD34 (stem/progenitor)
- CD138 (plasma cell)
Clinical notes
- X-linked agammaglobulinaemia: boys with almost no circulating B cells, very low immunoglobulins and bacterial infections after maternal IgG wanes (around 6 months).
- Rituximab (anti-CD20) removes most B cells but spares stem cells and plasma cells, so antibody levels fall only slowly.
- TdT and CD10 in a marrow blast population point to precursor (lymphoblastic) leukaemia.
Common traps
- XLA patients have B cells that simply fail to make antibody: they have almost no circulating B cells, because the block is at pre-B in the marrow.
- Babies with XLA are sick from birth: maternal IgG protects them for the first months, and infections start as it wanes (around 6 months).
- The light chain rearranges before the heavy chain: heavy chain comes first, then the pre-BCR checkpoint, then κ (λ only if κ fails).
- Rituximab stops antibody production quickly: plasma cells lack CD20, so existing antibody levels fall only slowly.
- Plasma cells carry CD20 like other B cells: they lose CD20 (and often CD19) and express CD38 and CD138.
Test yourself
Think of the answer, then tap the question to see it.
Why does a boy with XLA have normal T cells but almost no B cells in blood?
BTK is needed for pre-BCR signalling in B-cell precursors; without it they stop at the pre-B stage, while T-cell development uses other kinases.
Why does a functional heavy chain stop the other heavy-chain allele from rearranging?
Pre-BCR signalling switches off further heavy-chain rearrangement (allelic exclusion), so each B cell makes one heavy chain and has one specificity.
Why do antibody levels fall only slowly after rituximab?
Plasma cells do not express CD20, so existing plasma cells keep secreting antibody.
Elsewhere in DurgiPedia
Connections
In Pharmacology1
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: BTK gene (MedlinePlus Genetics, US National Library of Medicine, 2024); X-linked agammaglobulinemia (MedlinePlus Genetics, US National Library of Medicine, 2024); RAG1 gene (MedlinePlus Genetics, US National Library of Medicine, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
